Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest Content
Current issue
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest Content
Current issue
Archive
Authors
About
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Online First
Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
Adverse drug reactions
Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination
Free
Online download statistics by month:
Online download statistics by month: February 2022 to February 2023
Abstract
Full
Pdf
Feb 2022
452
443
109
Mar 2022
343
339
95
Apr 2022
380
379
59
May 2022
250
246
48
Jun 2022
118
120
31
Jul 2022
219
213
20
Aug 2022
144
139
24
Sep 2022
233
223
29
Oct 2022
123
125
29
Nov 2022
108
103
20
Dec 2022
86
83
15
Jan 2023
72
70
17
Feb 2023
71
65
9
Total
2599
2548
505
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF